1. Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation.
- Author
-
Maria Jose Lista, Pedro M Matos, Thomas J A Maguire, Kate Poulton, Elena Ortiz-Zapater, Robert Page, Helin Sertkaya, Ana M Ortega-Prieto, Edward Scourfield, Aoife M O'Byrne, Clement Bouton, Ruth E Dickenson, Mattia Ficarelli, Jose M Jimenez-Guardeño, Mark Howard, Gilberto Betancor, Rui Pedro Galao, Suzanne Pickering, Adrian W Signell, Harry Wilson, Penelope Cliff, Mark Tan Kia Ik, Amita Patel, Eithne MacMahon, Emma Cunningham, Katie Doores, Monica Agromayor, Juan Martin-Serrano, Esperanza Perucha, Hannah E Mischo, Manu Shankar-Hari, Rahul Batra, Jonathan Edgeworth, Mark Zuckerman, Michael H Malim, Stuart Neil, and Rocio Teresa Martinez-Nunez
- Subjects
Medicine ,Science - Abstract
There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform manual processing. We provide multiple workflows for SARS-CoV-2 nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral RNA Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind Viral DNA/RNA 96 Kit (Omega Bio-tek). We also compared One-step RT-qPCR reagents: TaqMan Fast Virus 1-Step Master Mix (FastVirus, ThermoFisher Scientific), qPCRBIO Probe 1-Step Go Lo-ROX (PCR Biosystems) and Luna® Universal Probe One-Step RT-qPCR Kit (Luna, NEB). We used primer-probes that detect viral N (EUA CDC) and RdRP. RNA extraction methods provided similar results, with Beckman performing better with our primer-probe combinations. Luna proved most sensitive although overall the three reagents did not show significant differences. N detection was more reliable than that of RdRP, particularly in samples with low viral titres. Importantly, we demonstrated that heat treatment of nasopharyngeal swabs at 70°C for 10 or 30 min, or 90°C for 10 or 30 min (both original variant and B 1.1.7) inactivated SARS-CoV-2 employing plaque assays, and had minimal impact on the sensitivity of the qPCR in clinical samples. These findings make SARS-CoV-2 testing portable in settings that do not have CL-3 facilities. In summary, we provide several testing pipelines that can be easily implemented in other laboratories and have made all our protocols and SOPs freely available at https://osf.io/uebvj/.
- Published
- 2021
- Full Text
- View/download PDF